µ²ºc¦¡ |
|
Fluticasone
(6,11,16,17)-6,9-difluoro-17-{[(fluoro-methyl)thio]carbonyl}- 11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate
Vilanterol
|
UpToDate |
UpToDate ³sµ²
|
ÃIJz§@¥Î |
|
¥Ñ©óRELVAR ELLIPTA§t¦³fluticasone furoate»Pvilanterol¨âºØ¦¨¤À¡A¦]¦¹¡A¥H¤UÃö©ó¨äÓ§O¦¨¤À¤§§@¥Î¾÷¨îªº»¡©ú¤]¾A¥Î©óRELVAR ELLIPTA¡C³o2ºØÃĪ«¤D¬O¤£¦PÃþ§OªºÃĪ«(¤@ºØ¬O¦X¦¨ªº¥Ö½èÃþ©T¾J¡A¤@ºØ¬OLABA)¡A¨ä¹ïÁ{§É«ü¼Ð»P¥Í²z«ü¼Ðªº¼vÅT¦U¤£¬Û¦P¡C Fluticasone Furoate¡GFluticasone furoate¬O¤@ºØ¦X¦¨ªº¤T¬t¤Æ¥Ö½èÃþ©T¾J¡A¨ã¦³§Üµoª¢ªº§@¥Î¡C Vilanterol¡GVilanterol¬O¤@ºØLABA¡C
£]2µÇ¤W¸¢¯À±µ¨üÅé§@¥Î¾¯(¥]¬Avilanterol)ªºÃIJz§@¥Î¦Ü¤Ö¦³¤@³¡¥÷¥iÂk¦]©ó¹ï²ÓM¤º¸¢苷»ÄÀô¤Æ酶ªº¨ë¿E§@¥Î¡A¦¹»Ã¯À¥i¶Ê¤Æ¸¢苷¤TÁC»Ä(ATP)Âà¤Æ¦¨3¡¦,5¡¦Àô¸¢苷³æÁC»Ä(ÀôAMP)ªº§@¥Î¡CÀôAMP¿@«×¤É°ª·|¾ÉP¤ä®ðºÞ¥·Æ¦ÙÃP¦¢¡A¨Ã·|§í¨î¥ß§Y©Ê¹L±Ó¤ÏÀ³´C¤¶ª«¦Û²ÓM(¤×¨ä¬OªÎ¤j²ÓM)¤¤ÄÀ¥Xªº§@¥Î¡C
|
¾AÀ³¯g |
|
1.ºC©Êªý¶ë©ÊªÍ¯fªººû«ùªvÀø¡G ºC©Êªý¶ë©ÊªÍ¯f(COPD)±wªÌ¤§®ð¹Dªý¶ë¯gª¬ªººû«ùªvÀø¡C °§C¦³´c¤Æ¯f¥v±wªÌ¤§COPD´c¤Æ¡C 2.®ð³ÝªºªvÀø¡G ªvÀø¾A¦X¨Ï¥Î§l¤J«¬¥Ö½èÃþ©T¾J¤Îªø®Ä£]2§@¥Î¾¯¦X¨Öªv療ªº18·³¤Î¥H¤W®ð³Ý±wªÌ¡C
|
¥Îªk¥Î¶q |
|
RELVAR ELLIPTA 92 mcg/22 mcg (»¼°e¾¯¶q)À³¥H¨C¤Ñ§l¤J¤@¦¸ªº¤è¦¡§ëÃÄ¡A¥B¶È¥i¸g¤f§l¤J¡C§l¤J¤§«á¡A±wªÌÀ³¥Î¤ôº¤¤f¡A¥B¤£¥i§]¤U¡A³o¬O¬°¤FÀ°§U°§Cµo¥Í¤f«|©À¯]µß¯fªº·ÀI¡C RELVAR ELLIPTAÀ³¨C¤Ñ©ó¬Û¦P®É¶¡§ëÃÄ¡C¨C24¤p®É¤£¥i¨Ï¥ÎRELVAR ELLIPTA¶W¹L1¦¸¡C ºC©Êªý¶ë©ÊªÍ¯f RELVAR ELLIPTA 92/22À³¥H¨C¤Ñ§l¤J¤@¦¸ªº¤è¦¡§ëÃÄ¡C³Ì¤j«Øij¾¯¶q¬°RELVAR ELLIPTA 92/22 mcg (»¼°e¾¯¶q)¨C¤Ñ§l¤J¤@¦¸(¥u¦³¸Ó¾¯¶q¾A¦X¥Î©óªvÀøCOPD)¡C ®ð³Ý «Øij°_©l¾¯¶q¬ORELVAR ELLIPTA 92/22©ÎRELVAR ELLIPTA184/22¨C¦¸§l¤J¤@³æ¦ì¾¯¶q¡A¨C¤Ñ¤@¦¸¡C
|
ÃİʤO¾Ç |
|
§l¦¬¡G Fluticasone Furoate¡G¦å¼ß¿@«×¥i¯àµLªk¹w´úªvÀøªº®ÄªG¡C¥i©ó0.5¦Ü1¤p®É¤º¹F¨ì¦y®p¦å¼ß¿@«×¡C§l¤J§ë¤©®É¡Afluticasone furoateªºµ´¹ï¥ÍÅé¥i¥Î²v¬°15.2%¡A¥Dn¬°§l¤J³¡¥÷ªº¾¯¶q¦b»¼°e¦ÜªÍ³¡«á³Q§l¦¬¶i¤JÅ餺©ÒP¡C§]Ã`³¡¥÷ªº¾¯¶q©Ò¾ÉPªº¤fªA¥ÍÅé¥i¥Î²v·¥§C(¬ù1.3%)¡A¦]¬°·|¸g¹L¼sªxªºº´ç¥NÁ¡CCOPD±wªÌ¤¤ªº¥þ¨ÃnÃĶq(AUC)n¤ñ°·±d¨ü¸ÕªÌ§C46%¡C Vilanterol¡GVilanterolªº¦å¼ß¿@«×¥i¯àµLªk¹w´úªvÀøªº®ÄªG¡C§l¤J«á¥i©ó10¤ÀÄÁ¤º¹F¨ì¦y®p¦å¼ß¿@«×¡C§l¤J§ë¤©®É¡Avilanterolªºµ´¹ï¥ÍÅé¥i¥Î²v¬°27.3%¡A¥Dn¬°§l¤J³¡¥÷ªº¾¯¶q¦b»¼°e¦ÜªÍ³¡«á³Q§l¦¬¶i¤JÅ餺©ÒP¡C§]Ã`³¡¥÷ªº¾¯¶q©Ò¾ÉPªº¤fªA¥ÍÅé¥i¥Î²v·¥§C(§C©ó2%)¡A¦]¬°·|¸g¹L¼sªxªºº´ç¥NÁ¡CCOPD±wªÌ¤¤ªº¥þ¨ÃnÃĶq(AUC)n¤ñ°·±d¨ü¸ÕªÌ°ª¥X24%¡C ¤À§G¡G Fluticasone Furoate¡G¹ï°·±d¨ü¸ÕªÌÀR¯ßª`®gµ¹ÃĤ§«á¡Aéwª¬ºA¤Uªº¥§¡¤À§GÅé¿n¬°661¤É¡CFluticasone furoate»P¤HÃþ¦å¼ß³J¥Õªºµ²¦X²v·¥°ª(99.6%)¡C Vilanterol¡G¹ï°·±d¨ü¸ÕªÌÀR¯ßª`®gµ¹ÃĤ§«á¡Aéwª¬ºA¤Uªº¥§¡¤À§GÅé¿n¬°165¤É¡CVilanterol»P¤HÃþ¦å¼ß³J¥Õªºµ²¦X²v¬°93.9%¡C ¥NÁ¡G Fluticasone Furoate¡GFluticasone furoate¦Û¥þ¨´`Àô¤¤³Q²M°£ªº¤è¦¡¥Dn¬O³z¹L¨xŦ¥NÁ¡AÂÇ¥ÑCYP3A4§Î¦¨¥Ö½èÃþ©T¾J¬¡©Ê©úÅã°§Cªº¥NÁª«¡C¥Ø«e¨ÃµL¥ô¦óÅ餺¸ÕÅ窺ÃÒ¾ÚÅã¥Üfuroate³¡¥÷·|µõ¸Ñ¨Ã¶i¤@¨B¾ÉP¥Í¦¨fluticasone¡C Vilanterol¡GVilanterol¥Dn¬O¸g¥ÑCYP3A4¥NÁ¦¨¤@¨t¦C1»P2§@¥Î¾¯¬¡©Ê©úÅã°§Cªº¥NÁª«¡C ±Æ°£¡G Fluticasone Furoate¡GFluticasone furoate¤Î¨ä¥NÁª«¥Dn³£¬O¸g¥ÑÁT«K±Æ¥XÅé¥~¡A±Æªn¶q¤À§O¬ù¬Û·í©ó¤fªA¾¯¶q»PÀR¯ßª`®g¾¯¶qªº101%»P90%¡C§¿²G¤¤ªº±Æªn¶q¤À§O¬ù¬Û·í©ó¤fªA¾¯¶q»PÀR¯ßª`®g¾¯¶qªº1%»P2%¡C¦b«½Æ§l¤Jµ¹ÃĤ§«á¡A¦å¼ß±Æ°£¶¥¬qªº¥b°I´Á¥§¡¬°24¤p®É¡C Vilanterol¡G¤fªAµ¹ÃĤ§«á¡Avilanterol¥Dn³£¬O¸g¥Ñ¥NÁ§@¥Î±Æ°£¡A¨ä¥NÁª«·|±Æ¤J§¿²G¤ÎÁT«K(±q¤¤¤À§O¦û¬ù70%¤Î30%ªº¦^¦¬©ñ®g¬¡©Ê¾¯¶q)¡C¦bCOPD±wªÌ¤¤¡A¨Ì¾Ú§l¤J
|
°Æ§@¥Î |
|
«|ª¢¡A»óÄuª¢¡A¤W©I§l¹D·P¬V¡C
|
¥æ¤¬§@¥Î |
|
²ÓM¦â¯ÀP450 3A4§í¨î¾¯ Fluticasone furoate»Pvilanterol (RELVAR ELLIPTAªºÓ§O¦¨¤À)¬Ò¬°CYP3A4ªº¨ü½è¡C»P±j®ÄªºCYP3A4§í¨î¾¯ketoconazole¦X¨Ö§ë¤©·|¤É°ªfluticasone furoate»Pvilanterolªº¥þ¨ÃnÃĶq¡C¦Ò¼{±NRELVAR ELLIPTA»Pªø´Á¨Ï¥Îªºketoconazole©Î¨ä¥L¤wª¾ªº±j®ÄCYP3A4§í¨î¾¯(¦pritonavir¡Bclarithromycin¡Bconivaptan¡Bindinavir¡Bitraconazole¡Blopinavir¡Bnefazodone¡Bnelfinavir¡Bsaquinavir¡Btelithromycin¡Btroleandomycin¡Bvoriconazole)¦X¨Ö§ë¤©®ÉÀ³ÂÔ·V¡C
|
¸T§Ò |
|
RELVAR ELLIPTA¸T¥Î©ó¤U¦Cª¬ªp¡G §@¬°«¿n©Ê®ð³Ý(status asthmaticus)©Î¨ä¥L«æ©ÊCOPD©Î®ð³Ýµo§@¥B¥²¶·±Ä¨ú±j®ÄªvÀø±¹¬Iªº²Ä¤@½uÀøªk¡C ¦³ÄY«¨Å³J¥Õ¹L±Ó°ÝÃD¡A©Î¤wÃÒ¹ê¹ïfluticasone furoate¡Bvilanterol©Î¥»«~¤§¥ô¦ó½á§Î¾¯¹L±Ó¡C
|
ª`·N¨Æ¶µ |
|
¹ï¯f±¡¥¿¦b§Ö³t´c¤Æ©Îµo¥Í¥i¯à¦M¤Î¥Í©R¤§µo§@¨Æ¥óªºCOPD±wªÌ¡A¤£¥i¶}©l¨Ï¥Î¥»«~¡C
|
ĵ»y |
|
ªø®Ä«¬ƒÒ2µÇ¤W¸¢¯À§@¥Î¾¯(LABA)·|¤É°ªµo¥Í®ð³Ý¬ÛÃö¦º¤`ªº·ÀI¡C¤@¶µ°w¹ï¦b¤@¯ë®ð³ÝªvÀø¤¤¥[¤J¥t¤@ºØLABA (salmeterol)©M¥[¤J¦w¼¢¾¯¤§¦w¥þ©Ê¤ñ¸ûªº¤j«¬¦w¼¢¾¯¹ï·Ó©Ê¬ü°ê¸ÕÅ窺¸ê®ÆÅã¥Ü¡A±µ¨üsalmeterolªvÀø¤§¨ü¸ÕªÌ¤¤ªº®ð³Ý¬ÛÃö¦º¤`¯f¨Ò¦³¼W¥[ªº²{¶H¡C³o¶µsalmeterolªº¬ÛÃöµo²{¤@¯ë»{¬°¬OLABA (¥]¬Avilanterol¡A§YRELVAR™ ELLIPTA™¤¤ªº¬¡©Ê¦¨¤À)ªºÃþ§O§@¥Î ¡C RELVAR ELLIPTA¥Î©ó®ð³Ý±wªÌªº¦w¥þ©Ê»PÀø®Ä©|¥¼½T¥ß¡CRELVAR ELLIPTA¨Ã¤£¾A¥Î©óªvÀø®ð³Ý¡C
|
¹L¶q³B²z |
|
¥Ø«e©|µL¤HÃþ¨Ï¥ÎRELVAR ELLIPTA¹L¶qªº¸ê®Æ¨£©ó³ø§i¡C
|
ÃÄ«~«O¦s¤è¦¡ |
|
Àx¦s©ó30¢J ¥H¤U¡C
|